In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections

Journal of Microbiology, Immunology and Infection

Volumn 40, Issue 6, 2007, Pages 481-486

  Tsai, Tung Yuan ^a   Chang, Shan Chwen ^b   Hsueh, Po Ren ^b   Feng, Nan Hsiung ^a   Wang, Jann Tay ^a,b  

^a KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Aminoglycosides; Antimicrobial sensitivity tests; Drug resistance, bacterial; Gram negative bacteria; Isepamicin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; GENTAMICIN; ISEPAMICIN; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BLOOD SAMPLING; CITROBACTER FREUNDII; DRUG ACTIVITY; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NEPHROTOXICITY; OTOTOXICITY; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; CROSS INFECTION; GENTAMICINS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; TAIWAN;

EID: 40649120440     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Miller GH, Sabatelli FJ, Naples L, Hare RS, Shaw KJ. The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin - a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups. J Chemother. 1995;7(Suppl 2):31-44.
2. Miller GH, Sabatelli FJ, Hare RS, Glupczynski Y, Mackey P, Shlaes D, et al. The most frequent aminoglycoside resistance mechanisms - changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis. 1997;24(Suppl 1):S46-62.
3. Vanhoof R, Nyssen HJ, Van Bossuyt E, Hannecart-Pokorni E. Aminoglycoside resistance in Gram-negative blood isolates from various hospitals in Belgium and the Grand Duchy of Luxembourg. Aminoglycoside Resistance Study Group. J Antimicrob Chemother. 1999;44:483-8.
4. Över U, Gür D, Ünal S, Miller GH; Aminoglycoside Resistance Study Group. The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey. Clin Microbiol Infect. 2001;7:470-8.
5. Siu LK. Antibiotics: action and resistance in gram-negative bacteria. J Microbiol Immunol Infect. 2002;35:1-11.
6. Goering RV, Sanders CC, Sanders WE Jr. In vivo analysis of structure-activity relationships among four aminoglycosides: gentamicin, netilmicin, 1-NHAPA gentamicin B and amikacin. Curr Ther Res. 1979;26:329-41.
7. Nagabhushan TL, Cooper AB, Tsai H, Daniels PJ, Miller GH. The syntheses and biological properties of 1-N-(S-4-amino-2-hydroxybutyryl)-gentamicin B and 1-N-(S-3-amino-2-hydroxypropionyl)-gentamicin B. J Antibiot (Tokyo). 1978;31:681-7.
8. Oshitani H, Kawai S, Kobayashi H. Experimental and clinical studies of HAPA-B. Chemotherapy (Tokyo). 1985;33(Suppl 5):201-5.
9. Takumida M, Nishida I, Nikaido M, Hirakawa K, Harada Y, Bagger-Sjöbäck D. Effect of dosing schedule on aminoglycoside ototoxicity: comparative cochlear ototoxicity of amikacin and isepamicin. ORL J Otorhinolaryngol Relat Spec. 1990;52:341-9.
10. Cheng NC, Hsueh PR, Liu YC, Shyr JM, Huang WK, Teng LJ, et al. In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan. Microb Drug Resist. 2005;11:330-41.
11. Liao CH, Sheng WH, Wang JT, Sun HY, Wang HK, Hsueh PR, et al. In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan. J Microbiol Immunol Infect. 2006;39:59-66.
12. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. 5th edition. NCCLS document M7-A6. Wayne, PA: National Committee for Clinical Laboratory Standards; 2004.
13. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing. 13th informational supplement. NCCLS document M100-S14 (M8). Wayne, PA: National Committee for Clinical Laboratory Standards; 2004.
14. Martin MA. Epidemiology and clinical impact of gram-negative sepsis. Infect Dis Clin North Am. 1991;5:739-52.
15. Hsueh PR, Chen ML, Sun CC, Chen WH, Pan HJ, Yang LS, et al. Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. Emerg Infect Dis. 2002:8;63-8.
16. Bryan CS, Reynolds KL, Brenner ER. Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis. 1983;5:629-38.
17. Craig WA. Once-daily versus multiple-daily dosing of aminoglycosides. J Chemother. 1995;7(Suppl 2):47-52.
18. Blum D. An overview of the safety of isepamicin in adults. J Chemother. 1995;7(Suppl 2):87-93.
19. Fauvelle F, Coulaud JM, Lecointre K, Tardy D, Poussel JF, Trape G. Comparison of two methods to obtain a desired first isepamicin peak in intensive care patients. Fundam Clin Pharmacol. 2001;15:151-6.
20. Jones RN. Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity. J Chemother. 1995;7(Suppl 2):7-16.
21. Miller GH, Chiu PJ, Waitz JA. Biological activity of SCH 21420, the 1-N-S-alpha-hydroxy-beta-aminopropionyl derivative of gentamicin B. J Antibiot (Tokyo). 1978;31:688-96.
22. Tod M, Minozzi C, Beaucaire G, Ponsonnet D, Cougnard J, Petitjean O. Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study. J Antimicrob Chemother. 1999;44:99-108.
23. Tod M, Padoin C, Petitjean O. Clinical pharmacokinetics and pharmacodynamics of isepamicin. Clin Pharmacokinet. 2000;38:205-23.
24. Vigano A, Principi N. A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients. J Chemother. 1995;7(Suppl 2):95-101.
25. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother. 1999;43:727-37.
26. Biswas SK, Kelkar RS. Invitro comparative evaluation of aminoglycosides at a cancer centre. Indian J Cancer. 2002;39:135-8.
27. Maltezou HC, Baka M, Gombakis N, Koliouskas DE, Kosmidou H, Malaka-Zafiriou E, et al. Comparison of isepamicin with amikacin for the empirical treatment of febrile neutropenic children with malignancies. Int J Antimicrob Agents. 2001;18:383-6.
28. Wu LT, Wu HJ, Chung JG, Chuang YC, Cheng KC, Yu WL. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 beta-lactamases at 2 hospitals in Taiwan. Diagn Microbiol Infect Dis. 2006;54:89-94.